Pacira Biosciences Inc reports results for the quarter ended in September - Earnings Summary

Pacira Biosciences

02/11/2023 14:11

* Pacira Biosciences Inc  PCRX.OQ  reported quarterly
adjusted
earnings of 72 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of 64 cents.  The mean expectation of
nine analysts for the quarter was for earnings of 78 cents per
share. Wall Street expected results to range from 68 cents to 87
cents per share.
    * Revenue fell 2.1% to $163.93 million from a year ago;
analysts
expected $171.63 million. 
    * Pacira Biosciences Inc's reported EPS for the quarter was
23
cents​.
    * The company reported quarterly net income of $10.86
million.
    * Pacira Biosciences Inc shares had fallen by 7.7% this
quarter and lost 26.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 4.4%
in the last three months.​ 
    * In the last 30 days, three analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Pacira
Biosciences Inc is $52.00 
This summary was machine generated from LSEG data November 2 at
02:11 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      0.78           0.72           Missed
 Jun. 30 2023      0.76           0.78           Beat
 Mar. 31 2023      0.62           0.53           Missed
 Dec. 31 2022      0.83           0.80           Missed